Sotalol
Sotalol. Class III antiarrhythmic + non-selective β-adrenergic blocker. Prolongs cardiac action potential via IKr blockade (class III) on top of… Oral half-life 7.2 h.
Class III antiarrhythmic + non-selective β-adrenergic blocker. Prolongs cardiac action potential via IKr blockade (class III) on top of β-blockade. Used for AF rhythm control + ventricular arrhythmias. QT prolongation requires inpatient initiation in many practices.
PK: zero-content — its citation reports only peak concentration and exposure. V 126 L is the EXACT MIDPOINT of a review "1.2-2.4 liters/kg" and F 0.95 the exact midpoint of "90-100%": two clean midpoints in one record. Both are dropped; the measured absolute bioavailability is 1.00 against an intravenous reference, and a genuine published absorption rate of 0.49 /h exists for the oral solution, which is stored with that formulation caveat since a tablet is slower. Half-life 7.2 h replaces an unsourced 12 h. THE EFFECT COMPARTMENT IS DEMOTED, NOT DELETED, because occupancy rows need one — but it is contradicted for the class-III action: "The correlation between the plasma concentration of (+/-)-sotalol and prolongation of QTc intervals was nearly linear, and SHOWED NO HYSTERESIS". Beta-blockade behaves oppositely, so one value cannot serve sotalol two actions either way. ANALYTE: this is a racemate in which only l-sotalol carries beta-blockade while both enantiomers block potassium channels, so a beta-blockade endpoint driven off total drug is over-driven about twofold. Renally cleared, so the half-life tracks creatinine clearance rather than being a constant.
Pharmacokinetics
- Oral — t½ 7.2 h · F 100% · ka 0.49 h⁻¹
- IV — t½ 7.2 h · F 100%
Sources: PMID:20562595, PMID:15655528, PMID:9643622, PMID:2373132, PMID:8951189, PMID:8573689